70 related articles for article (PubMed ID: 38438735)
21. Phase 1b/2 trial of fruquintinib plus sintilimab in treating advanced solid tumours: The dose-escalation and metastatic colorectal cancer cohort in the dose-expansion phases.
Guo Y; Zhang W; Ying J; Zhang Y; Pan Y; Qiu W; Fan Q; Xu Q; Ma Y; Wang G; Guo J; Su W; Fan S; Tan P; Wang Y; Luo Y; Zhou H; Li J
Eur J Cancer; 2023 Mar; 181():26-37. PubMed ID: 36628898
[TBL] [Abstract][Full Text] [Related]
22. Epigenetic-related gene mutations serve as potential biomarkers for immune checkpoint inhibitors in microsatellite-stable colorectal cancer.
Liu C; Xiao H; Cui L; Fang L; Han S; Ruan Y; Zhao W; Zhang Y
Front Immunol; 2022; 13():1039631. PubMed ID: 36479108
[TBL] [Abstract][Full Text] [Related]
23. Optimized dose selective HDAC inhibitor tucidinostat overcomes anti-PD-L1 antibody resistance in experimental solid tumors.
Zhang P; Du Y; Bai H; Wang Z; Duan J; Wang X; Zhong J; Wan R; Xu J; He X; Wang D; Fei K; Yu R; Tian J; Wang J
BMC Med; 2022 Nov; 20(1):435. PubMed ID: 36352411
[TBL] [Abstract][Full Text] [Related]
24. CXD101 and nivolumab in patients with metastatic microsatellite-stable colorectal cancer (CAROSELL): a multicentre, open-label, single-arm, phase II trial.
Saunders MP; Graham J; Cunningham D; Plummer R; Church D; Kerr R; Cook S; Zheng S; La Thangue N; Kerr D
ESMO Open; 2022 Dec; 7(6):100594. PubMed ID: 36327756
[TBL] [Abstract][Full Text] [Related]
25. PD-1 Blockade in Mismatch Repair-Deficient, Locally Advanced Rectal Cancer.
Cercek A; Lumish M; Sinopoli J; Weiss J; Shia J; Lamendola-Essel M; El Dika IH; Segal N; Shcherba M; Sugarman R; Stadler Z; Yaeger R; Smith JJ; Rousseau B; Argiles G; Patel M; Desai A; Saltz LB; Widmar M; Iyer K; Zhang J; Gianino N; Crane C; Romesser PB; Pappou EP; Paty P; Garcia-Aguilar J; Gonen M; Gollub M; Weiser MR; Schalper KA; Diaz LA
N Engl J Med; 2022 Jun; 386(25):2363-2376. PubMed ID: 35660797
[TBL] [Abstract][Full Text] [Related]
26. Trastuzumab deruxtecan in patients with central nervous system involvement from HER2-positive breast cancer: The DEBBRAH trial.
Pérez-García JM; Vaz Batista M; Cortez P; Ruiz-Borrego M; Cejalvo JM; de la Haba-Rodriguez J; Garrigós L; Racca F; Servitja S; Blanch S; Gion M; Nave M; Fernández-Abad M; Martinez-Bueno A; Llombart-Cussac A; Sampayo-Cordero M; Malfettone A; Cortés J; Braga S
Neuro Oncol; 2023 Jan; 25(1):157-166. PubMed ID: 35639825
[TBL] [Abstract][Full Text] [Related]
27. A phase I/Ib study of regorafenib and nivolumab in mismatch repair proficient advanced refractory colorectal cancer.
Kim RD; Kovari BP; Martinez M; Xie H; Sahin IH; Mehta R; Strosberg J; Imanirad I; Ghayouri M; Kim YC; Kim DW
Eur J Cancer; 2022 Jul; 169():93-102. PubMed ID: 35526308
[TBL] [Abstract][Full Text] [Related]
28. Pembrolizumab versus chemotherapy for microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer (KEYNOTE-177): final analysis of a randomised, open-label, phase 3 study.
Diaz LA; Shiu KK; Kim TW; Jensen BV; Jensen LH; Punt C; Smith D; Garcia-Carbonero R; Benavides M; Gibbs P; de la Fourchardiere C; Rivera F; Elez E; Le DT; Yoshino T; Zhong WY; Fogelman D; Marinello P; Andre T;
Lancet Oncol; 2022 May; 23(5):659-670. PubMed ID: 35427471
[TBL] [Abstract][Full Text] [Related]
29. HDAC Inhibition to Prime Immune Checkpoint Inhibitors.
Borcoman E; Kamal M; Marret G; Dupain C; Castel-Ajgal Z; Le Tourneau C
Cancers (Basel); 2021 Dec; 14(1):. PubMed ID: 35008230
[TBL] [Abstract][Full Text] [Related]
30. Low neoantigen expression and poor T-cell priming underlie early immune escape in colorectal cancer.
Westcott PMK; Sacks NJ; Schenkel JM; Ely ZA; Smith O; Hauck H; Jaeger AM; Zhang D; Backlund CM; Beytagh MC; Patten JJ; Elbashir R; Eng G; Irvine DJ; Yilmaz OH; Jacks T
Nat Cancer; 2021 Oct; 2(10):1071-1085. PubMed ID: 34738089
[TBL] [Abstract][Full Text] [Related]
31. First-Line Nivolumab Plus Low-Dose Ipilimumab for Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer: The Phase II CheckMate 142 Study.
Lenz HJ; Van Cutsem E; Luisa Limon M; Wong KYM; Hendlisz A; Aglietta M; García-Alfonso P; Neyns B; Luppi G; Cardin DB; Dragovich T; Shah U; Abdullaev S; Gricar J; Ledeine JM; Overman MJ; Lonardi S
J Clin Oncol; 2022 Jan; 40(2):161-170. PubMed ID: 34637336
[TBL] [Abstract][Full Text] [Related]
32. Regorafenib plus toripalimab in patients with metastatic colorectal cancer: a phase Ib/II clinical trial and gut microbiome analysis.
Wang F; He MM; Yao YC; Zhao X; Wang ZQ; Jin Y; Luo HY; Li JB; Wang FH; Qiu MZ; Lv ZD; Wang DS; Li YH; Zhang DS; Xu RH
Cell Rep Med; 2021 Sep; 2(9):100383. PubMed ID: 34622226
[TBL] [Abstract][Full Text] [Related]
33. POLE/POLD1 mutation in non-exonuclease domain matters for predicting efficacy of immune-checkpoint-inhibitor therapy.
Chen YX; Wang ZX; Yuan SQ; Jiang TJ; Huang YS; Xu RH; Wang F; Zhao Q
Clin Transl Med; 2021 Sep; 11(9):e524. PubMed ID: 34586735
[No Abstract] [Full Text] [Related]
34. Outcomes and toxicities of immune checkpoint inhibitors in colorectal cancer: a real-world retrospective analysis.
Zhou C; Jiang T; Li R; Yuan Y; Xie W; Huang X; Wang Q; Chang H; Chen G; Li Y; Zeng Z; Xiao W; Gao Y
Cancer Commun (Lond); 2021 Sep; 41(9):921-924. PubMed ID: 34327863
[No Abstract] [Full Text] [Related]
35. Regorafenib-Avelumab Combination in Patients with Microsatellite Stable Colorectal Cancer (REGOMUNE): A Single-arm, Open-label, Phase II Trial.
Cousin S; Cantarel C; Guegan JP; Gomez-Roca C; Metges JP; Adenis A; Pernot S; Bellera C; Kind M; Auzanneau C; Le Loarer F; Soubeyran I; Bessede A; Italiano A
Clin Cancer Res; 2021 Apr; 27(8):2139-2147. PubMed ID: 33495314
[TBL] [Abstract][Full Text] [Related]
36. Entinostat plus Pembrolizumab in Patients with Metastatic NSCLC Previously Treated with Anti-PD-(L)1 Therapy.
Hellmann MD; Jänne PA; Opyrchal M; Hafez N; Raez LE; Gabrilovich DI; Wang F; Trepel JB; Lee MJ; Yuno A; Lee S; Brouwer S; Sankoh S; Wang L; Tamang D; Schmidt EV; Meyers ML; Ramalingam SS; Shum E; Ordentlich P
Clin Cancer Res; 2021 Feb; 27(4):1019-1028. PubMed ID: 33203644
[TBL] [Abstract][Full Text] [Related]
37. Expert opinions on immunotherapy for patients with colorectal cancer.
Wang F; Wang ZX; Chen G; Luo HY; Zhang DS; Qiu MZ; Wang DS; Pan ZZ; Shen L; Li J; Zhang SZ; Xu RH
Cancer Commun (Lond); 2020 Oct; 40(10):467-472. PubMed ID: 32945625
[No Abstract] [Full Text] [Related]
38. HDAC Inhibitor, CG-745, Enhances the Anti-Cancer Effect of Anti-PD-1 Immune Checkpoint Inhibitor by Modulation of the Immune Microenvironment.
Kim YD; Park SM; Ha HC; Lee AR; Won H; Cha H; Cho S; Cho JM
J Cancer; 2020; 11(14):4059-4072. PubMed ID: 32368288
[TBL] [Abstract][Full Text] [Related]
39. Regorafenib Plus Nivolumab in Patients With Advanced Gastric or Colorectal Cancer: An Open-Label, Dose-Escalation, and Dose-Expansion Phase Ib Trial (REGONIVO, EPOC1603).
Fukuoka S; Hara H; Takahashi N; Kojima T; Kawazoe A; Asayama M; Yoshii T; Kotani D; Tamura H; Mikamoto Y; Hirano N; Wakabayashi M; Nomura S; Sato A; Kuwata T; Togashi Y; Nishikawa H; Shitara K
J Clin Oncol; 2020 Jun; 38(18):2053-2061. PubMed ID: 32343640
[TBL] [Abstract][Full Text] [Related]
40. HDAC inhibitors overcome immunotherapy resistance in B-cell lymphoma.
Wang X; Waschke BC; Woolaver RA; Chen SMY; Chen Z; Wang JH
Protein Cell; 2020 Jul; 11(7):472-482. PubMed ID: 32162275
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
